Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. is a medical technology company dedicated to developing and commercializing diagnostic and treatment modalities for patients suffering from sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and snoring. The company's mission is to provide clinically effective, non-surgical, non-invasive, non-pharmaceutical, and cost-effective solutions to improve breathing and sleep. Headquartered in Littleton, Colorado, Vivos Therapeutics aims to address the root causes of these conditions.

The company's core offering is The Vivos Method, a multidisciplinary treatment protocol that utilizes customized oral appliances. Key products include the Vivos CARE oral appliance therapy, encompassing DNA, mRNA, and mmRNA appliances. These devices are FDA 510(k) cleared for treating mild-to-severe OSA in adults, with the DNA appliance also cleared for moderate-to-severe pediatric OSA in children aged 6-17. Vivos also provides diagnostic tools like the VivoScore Program for at-home sleep testing, and services such as the Vivos Airway Intelligence Service (AIS) and Vivos Billing Intelligence Service (BIS).

Under the leadership of Chairman and CEO R. Kirk Huntsman, Vivos Therapeutics has recently focused on expanding its market reach through strategic acquisitions and collaborations. Notable developments include the acquisition of The Sleep Center of Nevada in June 2025, marking a pivot towards integrated sleep-center care and direct patient treatment. The company also reported a 16% increase in full-year 2025 revenue compared to 2024 and completed a private placement with New Seneca Partners in March 2026. Vivos continues to emphasize its FDA-cleared technologies as alternatives to traditional OSA treatments.